
FULC
Fulcrum Therapeutics Inc
Pharmaceuticals
Fulcrum Therapeutics Inc (FULC) Stock News
The latest FULC headlines and market coverage — 1 recent story, updated throughout the day.
- Benzinga·
FULC Stock Crashes After Hours: What Investors Need To Know
Fulcrum Therapeutics (NASDAQ: FULC) shares plunged 49.69% in after-hours trading after announcing the discontinuation of pociredir, its lead experimental drug for sickle cell disease, due to FDA concerns about cancer-related risks associated with PRC2 pathway targeting drugs. The company launched a strategic review process to explore merger, acquisition, or other alternatives to maximize shareholder value while preserving its $333.3 million in cash reserves.